Navigation Links
AHFS DI Essentials

ProductsAHFS DI Essentials
Company Skyscape, Inc.
Item AHFS DI Essentials
Features 
  • The monographs draw on the meticulously evidence-based guidelines, distilling for the health professional the essential information on prescription and key over-the-counter drugs in an easy-to-use, highly structured outline format
  • Important cautionary information on contraindications, warnings, sensitivity alerts, safe use in pregnant and breast-feeding women, adverse effects and drug interactions
  • Overview of the drug's pharmacologic actions and effects
  • Listing of dosages specific to each use, age group, route of administration and special population
  • Advice to patients
Description The mission of AHFS DI Essentials (American Hospital Formulary Service) is to provide an evidence-based foundation for safe and effective drug therapy.
Info Skyscape, Inc.
Customer Service: 508-460-6500
Web site: http://www.skyscape.com/index/home.aspx

Related medicine products :

1. Essentials of Diagnosis and Treatment 2nd Edition for PDA
2. Essentials of Diagnosis & Treatment in Surgery
3. Essentials of Diagnosis & Treatment in Cardiology
4. OcularEssentials® WHOLE BODY FORMULA
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Survivors of childhood cancer less likely to marry 10291 1Survivors of childhood cancer less likely to marry 10291 2HealthCare Partners IPA Dr Richard Merkin CEO Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington DC 5314 1HealthCare Partners IPA Dr Richard Merkin CEO Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington DC 5314 2HealthCare Partners IPA Dr Richard Merkin CEO Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington DC 5314 3Statewide Drug Card Program Launching 59108 1